Clinical Characteristics of Parkinsonism in HTLV-1-Associated Myelopathy

Mika Dozono1, Satoshi Nozuma1, Shota Hirakata1

  • 1Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Abstract

Insights

Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) with parkinsonism presents later in life and with greater severity. This study highlights the underrecognized coexistence of parkinsonism in HAM/TSP patients.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Virology

Background:

  • Human T-lymphotropic virus type 1 (HTLV-1) primarily causes HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
  • Neurological complications beyond HAM/TSP are recognized but less common.
  • Concurrent parkinsonism in HAM/TSP patients is rare and poses diagnostic challenges.

Purpose of the Study:

  • To identify the clinical characteristics of HAM/TSP patients who also exhibit parkinsonism.
  • To compare the clinical and demographic features of HAM/TSP with and without parkinsonism.

Main Methods:

  • Retrospective study of HAM/TSP patients hospitalized between January 2000 and March 2022.
  • Collected clinical and laboratory data from medical records.
  • Defined parkinsonism in HAM/TSP (P-HAM) based on specific motor symptoms not attributable to HAM/TSP and compared with typical HAM/TSP (T-HAM).

Main Results:

  • 11 out of 246 (4.5%) HAM/TSP patients presented with parkinsonism (P-HAM).
  • P-HAM patients had a significantly older age of onset (65.0 vs. 48.8 years) and higher disease severity (Osame Motor Disability Score ≥ 4) compared to T-HAM.
  • No significant differences in laboratory findings were observed between the groups.

Conclusions:

  • Parkinsonism occurs in a notable percentage of HAM/TSP patients, associated with later onset and increased severity.
  • The coexistence of parkinsonism in HAM/TSP may be underdiagnosed.
  • These findings broaden the understanding of the neurological manifestations of HTLV-1 infection.